LEXINGTON, Ky.--(BUSINESS WIRE)-- MedPro Safety Products, Inc. (OTCBB: MPSP.OB - News), a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced that it has passed its ISO 13485 recertification audit. The ISO 13485 standard represents the requirements for a comprehensive management system for the design and manufacture of medical devices.
“The recertification is a testament to MedPro’s commitment to quality,” said W. Craig Turner, Chairman and CEO of MedPro Safety Products. “We place the highest priority on ensuring our quality management system complies with the ISO Medical Device standard, FDA regulations and the Medical Device Directive. During this recertification process, we expanded the scope of the certificate to include the design and manufacture of fluid delivery devices. The updated scope reflected our expanding portfolio which will allow MedPro to further address three compelling, yet unmet needs in the market: clinician safety, patient safety and community safety.”
MedPro’s renewed certificate was awarded by BSI Group, a leading global independent business services organization providing standard-based assessments, certifications and solutions. The certification is effective until October 15, 2014.
About MedPro Safety Products, Inc.
Headquartered in Lexington, Kentucky, MedPro Safety Products, Inc. is a leading developer of safer medication delivery and blood collection systems. The Company licenses, develops and manufactures transformational technologies marketed through its global medical device partners. MedPro’s products address multiple product categories within the medication delivery (injection and infusion) and blood collection (blood collection sets and blood tube holders) markets. Unlike competitive products currently available on the market, MedPro’s products incorporate safety features that operate without user activation, and therefore require little or no clinician training to use. The total global market opportunity for safer medication delivery and blood collection products is believed to be more than $6 billion. For additional information, please refer to the ‘Investor Relations’ link on the Company’s website (www.medprosafety.com).
Safe Harbor Statement
This release includes forward-looking statements based upon current expectations of the management of MedPro Safety Products, Inc. that involve risks and uncertainties, such as plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including our ability to identify and acquire medical safety device safety technologies with product development potential; our ability to successfully develop and bring products to market, including obtaining regulatory approvals; our ability to successfully increase sales of our products; our ability to obtain additional financing on satisfactory terms; our ability to attract and retain qualified employees; and governmental regulation associated with the medical safety products industry. Words such as “anticipate,” “estimate,” “plan,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions are used to identify forward-looking statements. We refer you to the more detailed discussion of risks and uncertainties under “Risk Factors” in our Annual Report on Form 10-K and our other reports on file with the Securities and Exchange Commission.
Contact:. EVC Group Investor Contact: Doug Sherk/Jenifer Kirtland, 415-568-9349 Media Contact: Christopher Gale, 646-201-5431.
